Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)



Status:Recruiting
Conditions:Cardiology, Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:Any - 17
Updated:4/4/2019
Start Date:September 25, 2013
End Date:February 28, 2020
Contact:Boehringer Ingelheim Call Center
Email:clintriage.rdg@boehringer-ingelheim.com
Phone:1-800-243-0127

Use our guide to learn which trials are right for you!

Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age

The main objectives of this large phase IIb/III paediatric study are to assess the efficacy
and safety of dabigatran etexilate relative to standard of care and to document the
appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients
from birth to less than 18 years of age.


Inclusion criteria:

- Male or female subjects 0 to less than 18 years of age at the time of informed consent
/ assent

- Documented diagnosis of clinically stable VTE (e.g. DVT, PE, central line thrombosis,
sinus vein thrombosis) per investigator judgment, initially treated (minimum of 5 to 7
days, but not longer than 21 days) with parenteral anticoagulation therapy, such as
unfractionated heparin (UFH) or a low molecular weight heparin (LMWH).

- Clinical indication for at least 3 month of treatment with anticoagulants for the VTE
episode defined under the above inclusion criterion.

- Written informed consent provided by the patient's parent or legal guardian and assent
provided by the patient (if applicable) at the time of informed consent form (ICF)
signature according to local regulations.

Exclusion criteria:

- Conditions associated with an increased risk of bleeding

- Renal dysfunction (eGFR < 50 mL/min/1.73m^2 using the Schwartz formula) or requirement
for dialysis. eGFR retesting during the screening period is allowed (once).

- Active infective endocarditis

- Subjects with a heart valve prosthesis requiring anticoagulation.

- Hepatic disease:

Active liver disease, including known active hepatitis A, B or C or, Persistent alanine
aminotransferase (ALT) or aspartate transaminase (AST) or alkaline phosphatase (AP) > 3 ×
upper limit of normal (ULN) within 3 months of screening

- Pregnant or breast feeding females. Females who have reached menarche and are not
using a medically accepted contraceptive method per local guidelines. Acceptable
methods of birth control must be used in a correct and consistent manner

- Patients in stratum 3 (0 to < 2 years) with gestational age at birth < 37 weeks or
with body weight lower than the 3rd percentile

- Anemia (hemoglobin < 80g/L) or thrombocytopenia (platelet count < 80 x 109/L) at
screening. Transfusions during the screening period are allowed, provided that a
satisfactory hemoglobin or platelet level is attained prior to visit 2

- Patients who have taken prohibited or restricted medication within one week of the
first dose of study medication other than medication for prior VTE treatment and
P-glycoprotein inhibitors..

- Patients who have received an investigational drug in the past 30 days prior to
screening

- Patients who are allergic/sensitive to any component of the study medication including
solvent

- Patients or parents/legal guardians considered unreliable to participate in the trial
per investigator judgment or any condition which would present a safety hazard to the
patient based on investigator judgment

- Patients or parents/legal guardians who are unwilling or unable to undergo or permit
repeat of the baseline imaging tests required to confirm thrombus resolution at study
day 84 (or eEOT, whichever comes first) or in whom repeating such imaging tests at
these pre-specified time points may not be medically in the patient's best interest.
Examples may include unwarranted radiation exposure as a result of a repeat CT scan at
day 84 for a patient with an isolated case of pulmonary embolism evaluated at baseline
solely by a CT scan. In such cases, the baseline radiological assessment (e.g. CT) may
be supplemented with an acceptable non-radiological assessment at baseline (e.g. MRI)
which could then be repeated at day 84 hence alleviating any potential unwarranted
radiation exposure.

- Further exclusion criteria apply
We found this trial at
14
sites
101 W 8th Ave
Spokane, Washington 99204
(509) 474-3131
Providence Sacred Heart Medical Center & Children's Hospital When Mother Joseph and the Sisters of...
?
mi
from
Spokane, WA
Click here to add this to my saved trials
1200 Pleasant Street
Des Moines, Iowa 50309
(515) 241-KIDS
Blank Children's Hospital Blank Children's Hospital is completely dedicated to meeting the unique health care...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Caba,
Click here to add this to my saved trials
1215 Lee St
Charlottesville, Virginia 22903
(434) 924-0211
University of Virginia Health System UVA Health System includes a 604-bed hospital, level I trauma...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
200 Hawkins Dr,
Iowa City, Iowa 52242
866-452-8507
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Las Vegas, Nevada 89109
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
2450 Riverside Avenue
Minneapolis, Minnesota 55454
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1 Shields Ave
Sacramento, California 95616
(530) 752-1011
University of California-Davis As we begin our second century, UC Davis is poised to become...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63104
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials